blonanserin has been researched along with mdl 100907 in 5 studies
| Studies (blonanserin) | Trials (blonanserin) | Recent Studies (post-2010) (blonanserin) | Studies (mdl 100907) | Trials (mdl 100907) | Recent Studies (post-2010) (mdl 100907) |
|---|---|---|---|---|---|
| 121 | 21 | 93 | 1,241 | 65 | 539 |
| Protein | Taxonomy | blonanserin (IC50) | mdl 100907 (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0048 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishibashi, T; Nakamura, H; Nishikawa, H; Une, T | 1 |
| Imaki, J; Ohno, Y; Okano, M; Okumura, T; Shimizu, S; Tatara, A | 1 |
| Horiguchi, M; Meltzer, HY | 1 |
| Huang, M; Kwon, S; Meltzer, HY; Oyamada, Y; Panos, JJ; Rajagopal, L | 1 |
| Baba, S; Enomoto, T; Hashimoto, T; Horisawa, T; Ono, M | 1 |
1 review(s) available for blonanserin and mdl 100907
| Article | Year |
|---|---|
[Pharmacological profiles and clinical effects of blonanserin (Lonasen) on schizophrenia].
Topics: Animals; Antidepressive Agents, Second-Generation; Cognition Disorders; Dopamine D2 Receptor Antagonists; Double-Blind Method; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Humans; Piperazines; Piperidines; Randomized Controlled Trials as Topic; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2008 |
4 other study(ies) available for blonanserin and mdl 100907
| Article | Year |
|---|---|
Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Haloperidol; Male; Mice; Mice, Inbred Strains; Nucleus Accumbens; Piperazines; Piperidines; Proto-Oncogene Proteins c-fos; Pyridines; Serotonin 5-HT2 Receptor Antagonists | 2010 |
Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: role of indirect 5-HT(1A) partial agonism.
Topics: Animals; Female; Isoindoles; Phencyclidine; Piperazines; Piperidines; Pyridines; Pyrimidines; Rats; Rats, Long-Evans; Receptor, Serotonin, 5-HT1A; Recognition, Psychology; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists | 2013 |
Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Brain; Cerebral Cortex; Dopamine; Glutamic Acid; Hippocampus; Isoindoles; Lurasidone Hydrochloride; Male; Microdialysis; Neurotransmitter Agents; Nucleus Accumbens; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Synaptic Transmission; Thiazoles | 2014 |
Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
Topics: Animals; Antipsychotic Agents; Cells, Cultured; Cricetinae; Cricetulus; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Hyperkinesis; Male; Piperazines; Piperidines; Protein Binding; Rats, Sprague-Dawley; Receptors, Dopamine D3; Serotonin 5-HT2 Receptor Antagonists | 2015 |